The Role of Adjuvant 1.25-Dihidroxyvitamin D3 on CD4+CD25+CD127low Regulatory T-cell in Subcutaneous Allergen Specific Immunotherapy
Saturday, March 3, 2018
South Hall A2 (Convention Center)
Melati Sudiro, Teti Madiadipoera, Thaufiq Siddiq Boesoirie, Budi Setiabudiawan
RATIONALE: 1,25 Dihydroxyvitamin D3, the active form of vitamin D has been reported to inhibit proliferation of effector cells and to enhance CD4+CD25+CD127low regulatory T-cells. We hypothesized that using the active form of vitamin D as an adjuvant would enhanced CD4+CD25+CD127lowregulatory T-cells as well as the anti-inflammatory cytokines of allergic rhinitis patient undergoing subcutaneous immunotherapy (SCIT).

METHODS:It was a randomized, double-blind, placebo-controlled trial conducted in 36 allergic rhinitis patients who suffer vitamin D deficiency; age 18-49 years. The intervention based on patient treated with SCIT–calcitriol 0.5 mcg/day and SCIT–placebo as the control group on immunotherapy build-up phase. All groups evaluated at baseline, week 8 and week 15 for proportion CD4+CD25+CD127low regulatory T-cells using flow cytometry, IL-10, and TGF-β using ELISA. Nasal symptoms score using Visual Analoq Scale. The Mann Whitney test, Friedman test and post-hoc test using Wilcoxon used for statistical analysis.

RESULTS: The proportions of CD4+CD25+CD127low regulatory T-cells significantly increased in the intervention group compared with control (p=0.04) in week 8. There was a significant and positive tren in the increase of anti -inflammatory cytokines in the intervention group at week 8, particulary in IL-10 (p=0.035) and TGF-β (p=0.001), whereas control groups show after the week 15. The decrease in nasal symptoms score did not differ significantly between groups (p>0.05).

CONCLUSIONS: Immunologic outcomes changes start in week 8 in SCIT with 1.25-Dihidroxyvitamin D3 group. However, clinical improvement was mostly similar between groups. 1.25-Dihidroxyvitamin D3 a promising adjuvant for the improvement of SCIT.